[1] 张建民.动脉瘤性蛛网膜下腔出血诊治热点问题及展望[J].浙江大学学报:医学版,2015,44(4):357-360.
[2] LIU J,SONG J,ZHAO D,et al.Risk factors responsible for the volume of hemorrhage in aneurysmal subarachnoid hemorrhage[J].Neurol India,2016,64(4):686-691.
[3] 付超,赵丛海.动脉瘤性蛛网膜下腔出血后早期脑损伤病理生理的研究进展[J].中华神经医学杂志,2013,12(10):1073-1076.
[4] 王毅,王东,尉辉杰,等.早期血清血管生成素变化对蛛网膜下腔出血患者预后的影响[J].中华医学杂志,2015,95(19):1513-1517.
[5] CHITTIBOINA P,GANTA V,MONCEAUX C P,et al.Angiopoietins as promising biomarkers and potential therapeutic targets in brain injury[J].Pathophysiology,2013,20(1):15-21.
[6] KARAKUS S,BOZOKLUAKKAR O,YILDIZ C,et al.Serum levels of ET-1,M30,and angiopoietins-1 and-2 in HELLP syndrome and preeclampsia compared to controls[J].Arch Gynecol Obstet,2016,293(2):351-359.
[7] ATESOGLU E B,TARKUN P,MEHTAP O,et al.Serum angiopoietin levels are different in acute and chronic myeloid neoplasms:angiopoietins do not only regulate tumor angiogenesis[J].Indian J Hematol Blood Transfus,2016,32(2):162-167.
[8] ZENG H,HE X,TUO Q H,et al.LPS causes pericyte loss and microvascular dysfunction via disruption of Sirt3/angiopoietins/Tie-2 and HIF-2α/Notch3 pathways[J].Sci Rep,2016,12(6):1038-1051.
[9] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国蛛网膜下腔出血诊治指南2015[J].中华神经科杂志,2016,49(3):182-191.
[10] ZENG H,HE X,TUO Q H,et al.LPS causes pericyte loss and microvascular dysfunction via disruption of Sirt3/angiopoietins/Tie-2 and HIF-2α/Notch3 pathways[J].Sci Rep,2016,12(6):1038-1051.
[11] 闫薪如,冯娟.血清血管生成素1水平与急性脑梗死发病、病情严重程度及90d预后的关系[J].临床神经病学杂志,2016,29(2):113-116.
[12] 颜芳,欧希龙.血管生成素-1和2在肿瘤血管生成中的作用[J].现代医学,2007,35(1):75-78.
[13] CHITTIBOINA P,GANTA V,MONCEAUX C P,et al.Angiopoietins as promising biomarkers and potential therapeutic targets in brain injury[J].Pathophysiology,2013,20(1):15-21.
[14] WEI H J,WANG D,CHEN J L,et al.Mobilization of circulating endothelial progenitor cells after endovascular therapy for ruptured cerebral aneurysms[J].Neurosci Lett,2011,498(2):114-118.
[15] 王新刚,吴攀,韩春茂.血管生成素促进血管新生机制及其应用研究进展[J].中华烧伤杂志,2015,31(6):473-475. |